Business context and reporting period
This is Sigma Labs, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, comparing results with 2014; it is not a standalone fourth-quarter report. The request metadata names Nexttrip, Inc., but the filing identifies the registrant as Sigma Labs, Inc. Investors should verify the issuer and filing before relying on this summary.
Sigma develops manufacturing and materials technologies, with its main focus on PrintRite3D in-process quality assurance for metal additive manufacturing (3D printing), related engineering services, and contract manufacturing. On December 29, 2015, its operating subsidiary B6 Sigma merged into Sigma Labs.
Key financial metrics
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $1,234,810 | $548,723 |
| Gross profit | $1,020,806 | $389,787 |
| Gross margin | 82.7% | 71.0% |
| Net loss | $(1,696,282) | $(3,116,080) |
| Operating cash used | $(1,259,685) | $(888,560) |
| Cash at year-end | $1,539,809 | $2,962,069 |
| Working capital surplus | $1,785,728 | $2,811,606 |
| Total liabilities | $109,916 | $354,350 |
2015 revenue included approximately $1,164,709 from PrintRite3D-enabled engineering consulting and $70,101 from metal 3D-printing contract manufacturing. The filing reports no interest expense or credit facilities. Revenue and profit margins reflect a services-led business, not yet scaled product licensing.
Material changes versus 2014
- Revenue increased approximately 125%, primarily from additional contracts; gross margin rose about 11.7 percentage points.
- Net loss narrowed by approximately 46%, partly because 2014 included a non-recurring $1,283,333 warrant-extension expense. Higher revenue also offset increases in general and administrative, payroll, and R&D costs.
- Cash declined by $1,422,260. Operating cash use increased, while investing cash use fell to $162,575 from $839,610, largely because the EOS M290 printer was purchased in 2014. No financing cash was raised in 2015; 2014 financing provided $3,697,791 net.
- Shares outstanding increased: the balance sheet reports 620,657,335 common shares outstanding at year-end 2015 versus 612,741,061 at year-end 2014. The filing also reports 622,969,835 shares outstanding as of March 15, 2016.
Outlook, risks and unusual items
Management expected sufficient funds for operations through 2016, based on cash, expected contract receipts, product and service sales, and possible securities offerings. It also stated that further capital would be needed to fulfill its plans if significant product and contract-manufacturing revenues did not materialize. As of March 16, 2016, seven active contracts were expected to generate up to approximately $690,000 in 2016, subject to performance milestones and customer non-termination. This is a contingent estimate, not formal revenue guidance.
Management expected to continue commercializing PrintRite3D in 2016 and 2017 and anticipated increased operating, payroll, and commercialization costs. Key risks include ongoing losses and operating cash burn, dependence on future financing and potential shareholder dilution, early-stage commercialization, competition, contract and milestone uncertainty, and concentration in a small number of customers. In 2015, one customer represented 42.93% of revenue; three customers together represented about 72.6%. There is no clear debt-balance disclosure beyond the reported liabilities; the balance sheet lists accounts payable and accrued expenses and no interest expense.
The company reported that its disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an internal-control attestation. The financial statements received an unqualified audit opinion. No legal proceedings were reported. The Arete-Sigma joint venture had a 2015 equity-method loss of $778, and the company said it intended to terminate the venture in the first half of 2016 while continuing to pursue additive-manufacturing opportunities.
Important facts for investors to verify
- Confirm that Sigma Labs, Inc.—not Nexttrip, Inc.—is the intended issuer and that the fiscal-year 2015 filing is the intended period.
- Review audited statements and notes for the composition and timing of revenue, cash use, customer concentration, and the conditional 2016 contract estimate.
- Assess whether commercialization, licensing, and contract manufacturing can grow enough to reduce losses and dependence on additional capital.
- Check subsequent filings for financing, share-count changes, warrant or option activity, and the outcome of the planned joint-venture termination.
- Consider the filing’s stated risks around limited operating history, customer and contract dependence, dilution, and the volatility and trading constraints associated with its OTCQB-listed common stock.